Crohn's disease management after intestinal resection: A randomised trial

The Lancet

Volumn 385, Issue 9976, 2015, Pages 1406-1417

  De Cruz, Peter ^a   Kamm, Michael A ^a,b   Hamilton, Amy L ^a   Ritchie, Kathryn J ^a   Krejany, Efrosinia O ^a   Gorelik, Alexandra ^a   Liew, Danny ^a   Prideaux, Lani ^a   Lawrance, Ian C ^c   Andrews, Jane M ^d   Bampton, Peter A ^e   Gibson, Peter R ^f   Sparrow, Miles ^g   Leong, Rupert W ^h   Florin, Timothy H ⁱ   Gearry, Richard B ^j   Radford Smith, Graham ^k   Macrae, Finlay A ^a   Debinski, Henry ^l   Selby, Warwick ^m   Kronborg, Ian ⁿ   Johnston, Michael J ^a   Woods, Rodney ^a   Elliott, P Ross ^a   Bell, Sally J ^a   Brown, Steven J ^a   Connell, William R ^a   Desmond, Paul V ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g Flinders University ^*  (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j UNIVERSITY OF OTAGO   (New Zealand)

^k QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^l CABRINI HOSPITAL   (Australia)

^m ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁿ Western Hospital   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; MERCAPTOPURINE; METRONIDAZOLE; AZATHIOPRINE; MONOCLONAL ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COLON RESECTION; COLONOSCOPY; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; ILEUM RESECTION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE RESECTION; JEJUNUM ULCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT PREFERENCE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; RISK FACTOR; SIGMOIDECTOMY; TREATMENT FAILURE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 84928704222     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61908-5     Document Type: Article

References (42)

1. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
2. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50.
3. Munkholm P, Langholz E, Davidsen M., Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23.
4. Cosnes J, Nion-Larmurier I, Beaugerie L., Afchain P, Tiret E, Gendre JP Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
5. Peyrin-Biroulet L., Harmsen WS, Tremaine W.J., Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012; 107: 1693-701.
6. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-35.
7. Rutgeerts P, Geboes K, Vantrappen G., Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665-72.
8. Rutgeerts P, Geboes K, Vantrappen G., Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63.
9. Landsend E, Johnson E, Johannessen H-O, Carlsen E. Long-term outcome after intestinal resection for Crohn's disease. Scand J Gastroenterol 2006; 41: 1204-08.
10. Reese GE, Nanidis T, Borysiewicz C., Yamamoto T, Orchard T, Tekkis PP The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-21.
11. Simillis C, Yamamoto T, Reese G.E., et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol 2008; 103: 196-205.
12. McLeod RS, WolffB G, Ross S, Parkes R, McKenzie M, and the Investigators of the CAST Trial. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009; 52: 919-27.
13. Van Assche G., Dignass A, Reinisch W., et al, and the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohn' s Colitis 2010; 4: 63-101.
14. Rutgeerts P, Van Assche G. What is the role of endoscopy in the postoperative management of Crohn's disease? Inflamm Bowel Dis 2008; 14 (suppl 2): S179-80.
15. Rutgeerts P, Hiele M, Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21.
16. D'Haens G.R., Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-29.
17. Regueiro M, Schraut W, Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-50.
18. Sorrentino D, Terrosu G, Avellini C., Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167: 1804-07.
19. Regueiro M, Kip KE, Baidoo L, Swoger J.M., Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol 2014; 12: 1494-502, e1.
20. Van Assche G., Dignass A, Panes J., et al, and the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohn' s Colitis 2010; 4: 7-27.
21. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-89.
22. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
23. De Cruz P., Kamm MA, Prideaux L, Allen P.B., Desmond PV. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012; 18: 758-77.
24. Savarino E, Bodini G, Dulbecco P., et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013; 108: 1731-42.
25. De Cruz P., Kamm MA, Hamilton A.L., et al. Adalimumab prevents post-operative Crohn's disease recurrence, and is superior to thiopurines: early results from the POCER study. Gastroenterology 2012; 142: S-212.
26. Sachar DB, Lemmer E, Ibrahim C., et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis 2009; 15: 1071-75.
27. Doherty GA, Miksad RA, Cheifetz A.S., Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis 2012; 18: 1608-16.
28. Ananthakrishnan AN, Hur C, Juillerat P., Korzenik JR. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011; 106: 2009-17.
29. Ng SC, Lied GA, Arebi N, Phillips R.K., Kamm MA. Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit. Eur J Gastroenterol Hepatol 2009; 21: 551-57.
30. De Cruz P., Bernardi MP, Kamm M.A., et al. Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment step-up. Colorectal Dis 2013; 15: 187-97.
31. Rutgeerts P, Diamond RH, Bala M, et al Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42.
32. Frøslie K.F., Jahnsen J, Moum B.A., Vatn MH, and the IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
33. Schnitzler F, Fidder H, Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
34. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2012; 138: 463-68.
35. Regueiro M, Baidoo L, Kip K.E., et al. infliximab maintenance beyond one year prevents postoperative crohn's disease recurrence: long-term follow-up from the randomized controlled pilot study. Gastroenterol 2013; 144 (suppl 1): S-173.
36. Aguas M, Bastida G, Cerrillo E., et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 2012; 18: 4391-98.
37. Papamichael K, Archavlis E, Lariou C., Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohn' s Colitis 2012; 6: 924-31.
38. Colombel JF, Sandborn WJ, Reinisch W, et al., and the SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
39. Hébuterne X., Lémann M, Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62: 201-08.
40. Rutgeerts P, Van Assche G, Sandborn WJ, et al Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11.
41. Viscido A, Corrao G, Taddei G., Caprilli R. "Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Ital J Gastroenterol Hepatol 1999; 31: 274-79.
42. Walters TD, Steinhart AH, Bernstein C.N., et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011; 17: 1547-56.